These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35173817)

  • 1. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
    Addeo A; Hochmair M; Janzic U; Dudnik E; Charpidou A; Płużański A; Ciuleanu T; Donev IS; Elbaz J; Aarøe J; Ott R; Peled N
    Ther Adv Med Oncol; 2021; 13():17588359211059874. PubMed ID: 35173817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
    Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
    Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns, Testing Practices, and Outcomes in Patients with
    Pluzanski A; Bryl M; Chmielewska I; Czyzewicz G; Luboch-Kowal J; Wrona A; Samborska A; Krzakowski M
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
    Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
    Janžič U; Turnšek N; Dediu M; Donev IS; Lupu R; Teodorescu G; Ciuleanu TE; Pluzanski A
    Curr Oncol; 2022 Aug; 29(8):5833-5845. PubMed ID: 36005198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.
    Cuppens K; Lodewyckx L; Demedts I; Decoster L; Colinet B; Deschepper K; Janssens A; Galdermans D; Pieters T;
    Drugs Real World Outcomes; 2021 Jun; 8(2):141-152. PubMed ID: 33710523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world management patterns in
    Lampaki S; Mountzios G; Georgoulias V; Rapti A; Xanthakis I; Baka S; Mavroudis D; Samantas E; Athanasiadis E; Zagouri F; Charpidou A; Somarakis A; Papista C; Nikolaou A; Anastasopoulou E; Paparepa Z; Syrigos KN
    Future Oncol; 2022 Sep; 18(28):3151-3164. PubMed ID: 35929414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review.
    Shah R; Girard N; Nagar SP; Griesinger F; Roeper J; Davis KL; Karimi P; Sawyer W; Yu N; Taylor A; Feliciano J
    Drugs Real World Outcomes; 2021 Dec; 8(4):537-545. PubMed ID: 34533784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases.
    Soo RA; Seto T; Gray JE; Thiel E; Taylor A; Sawyer W; Karimi P; Marchlewicz E; Brouillette M
    Drugs Real World Outcomes; 2022 Mar; 9(1):31-41. PubMed ID: 34510401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
    Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
    Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
    Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
    Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
    Popat S; Ahn MJ; Ekman S; Leighl NB; Ramalingam SS; Reungwetwattana T; Siva S; Tsuboi M; Wu YL; Yang JC
    Target Oncol; 2023 Jan; 18(1):9-24. PubMed ID: 36652172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of patient characteristics, treatment patterns,
    Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J
    Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.
    Magios N; Bozorgmehr F; Volckmar AL; Kazdal D; Kirchner M; Herth FJ; Heussel CP; Eichhorn F; Meister M; Muley T; Elshafie RA; Fischer JR; Faehling M; Kriegsmann M; Schirmacher P; Bischoff H; Stenzinger A; Thomas M; Christopoulos P
    Ther Adv Med Oncol; 2021; 13():1758835921996509. PubMed ID: 34408792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
    Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.